Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01275 (glucagon)
 26,492 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Octreotide is a long-acting cyclic octapeptide with pharmacologic actions mimicking those of the natural hormone somatostatin. It can suppress the secretion of serotonin, as well as the gastroenteropancreatic peptides gastrin, vasoactive intestinal peptide (VIP), insulin, glucagon, secretin, motilin, and pancreatic polypeptide. It also suppresses growth hormone and decreases splanchnic blood flow. Octreotide is completely and rapidly absorbed following subcutaneous injection and has an elimination half-life of 1.5 hours. Clinical trials reviewed here show octreotide useful in the treatment of diarrhea associated with VIP secreting tumors, as well as diarrhea and flushing associated with carcinoid syndrome, both conditions for which the drug is approved. Clinical trials involving the use of octreotide in the treatment of acromegaly are also reviewed. Adverse reactions to octreotide are mild to moderate and most commonly involve injection site pain and diarrhea. Drug interactions are apparently related to the drug's pharmacologic effects. Octreotide is given subcutaneously two to three times daily, with daily doses ranging from 50mcg to 1,500mcg per day. Further research appears necessary to clarify dosing issues.
Conn Med 1989 Dec
PMID:Debut of a somatostatin analog: octreotide in review. 255 39

A 2013 review concludes that postmeal exercise is better than premeal exercise for managing hyperglycemia. The ideal scenario for diabetes patients is to use up the glucose from the meal as fuel for exercise rather than bring additional endogenous glucose into the blood. This is readily done by timing the exercise tactically: let a physical activity of moderate intensity coincide with the build-up of glucose in the blood from the meal. At this time insulin-to-glucagon ratio is high and hepatic glucose production is inhibited. Data scattered over several studies, when considered together, show that about 30 minutes postmeal is the time to start a moderate-intensity exercise for optimal efficacy. Exercising at other times--before breakfast, right after a meal, or late in the postprandial period--leads to exertion-related glucose elevation and the patients miss a unique opportunity to blunt the meal-related glucose peak.
Conn Med 2014 Oct
PMID:Why exercise before breakfast may not be for diabetes patients. 2567 89